Literature DB >> 12954496

Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.

Jason R Gee1, Roselina G Montoya, Hussein M Khaled, Anita L Sabichi, H Barton Grossman.   

Abstract

Bladder tumors from Egyptian patients with a high prevalence of bilharziasis were immunohistochemically analyzed for the expression of cytokeratin 20 (CK20), AN43, prostaglandin dehydrogenase (PGDH), and cyclooxygenase-2 (COX-2). The tumors included 26 transitional cell carcinomas (TCC), 10 squamous cell carcinomas (SCC) and 2 tumors of mixed TCC/SCC histology. Of the 28 TCC tumors, 21 (75%) expressed CK20 and 25 (89%) expressed AN43. CK20 was not expressed in any of the 10 SCC tumors and AN43 was expressed in 2 of them. PGDH was expressed in 18 (64%) of the 28 tumors with TCC histology and 1 of the 10 SCC. A subset of 21 tumors (16 TCC and 5 SCC) was tested for COX-2 expression. COX-2 was detected in 69% of the 16 TCC tumors examined but was not seen in the SCC tumors. As tumors increased in stage, the expression of these proteins changed. CK20, AN43 and PGDH decreased but COX-2 expression increased in higher stage tumors. The histologic phenotype of these cancers is reflected in their expression of these proteins and is modified further as tumors progress in stage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954496     DOI: 10.1016/s1078-1439(02)00271-5

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  18 in total

Review 1.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

2.  Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer.

Authors:  Jason R Gee; Corrie B Burmeister; Thomas C Havighurst; Kyungmann Kim
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

3.  Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis.

Authors:  Rui M Gil da Costa; Paula A Oliveira; Carmen Vasconcelos-Nóbrega; Regina Arantes-Rodrigues; Rosário Pinto-Leite; Aura A Colaço; Luis F de la Cruz; Carlos Lopes
Journal:  Int J Exp Pathol       Date:  2015-10-30       Impact factor: 1.925

4.  Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer.

Authors:  Nadine T Gaisa; Till Braunschweig; Nina Reimer; Jörg Bornemann; Elke Eltze; Sabine Siegert; Marieta Toma; Luigi Villa; Arndt Hartmann; Ruth Knuechel
Journal:  Virchows Arch       Date:  2010-12-07       Impact factor: 4.064

Review 5.  15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer.

Authors:  Hsin-Hsiung Tai; Min Tong; Yunfei Ding
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-01-17       Impact factor: 3.072

Review 6.  Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂.

Authors:  Jessica K Norberg; Earlphia Sells; Hui-Hua Chang; Srinivas R Alla; Shuxing Zhang; Emmanuelle J Meuillet
Journal:  Pharm Pat Anal       Date:  2013-03

7.  NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer.

Authors:  Duncan Hughes; Taisuke Otani; Peiying Yang; Robert A Newman; Rhonda K Yantiss; Nasser K Altorki; Jeff L Port; Min Yan; Sanford D Markowitz; Madhu Mazumdar; Hsin-Hsiung Tai; Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2008-09

8.  Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors.

Authors:  Hung Pham; Monica Chen; Aihua Li; Jonathan King; Eliane Angst; David W Dawson; Jenny Park; Howard A Reber; O Joe Hines; Guido Eibl
Journal:  Pancreas       Date:  2010-04       Impact factor: 3.327

9.  Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice.

Authors:  John A Taylor; Benjamin Ristau; Mathilde Bonnemaison; Olga S Voznesensky; Poornima Hegde; George A Kuchel; Carol C Pilbeam
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-09-12       Impact factor: 3.072

Review 10.  An inflammatory mediator, prostaglandin E2, in colorectal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.